Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.

We believe that the use of the paracetamol technique in isolation to evaluate the effects of GLP-1RAs on gastric emptying in humans should be abandoned and that scintigraphic measurement, using a standardized technique, should represent a mandatory regulatory requirement in the development of this drug class, including oral semaglutide. We have also pointed out that it is incorrect to suggest that a reduction in the AUC 0 to 1 hours, but not the AUC 0 to 5 hours, for paracetamol, indicates that an effect to slow gastric emptying is only sustained for 1 hour,2 simply because it may be anticipated that all the paracetamol will eventually be absorbed. [Extracted from the article]